Published in J Nucl Med on November 01, 1998
The Study of the Impact of Disclosing Imaging Study Information to Trial Participants | NCT00354003
Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab (2006) 2.42
[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 1.56
Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging (2006) 1.50
Comparison between Different Intensity Normalization Methods in 123I-Ioflupane Imaging for the Automatic Detection of Parkinsonism. PLoS One (2015) 1.44
Structural and functional imaging in parkinsonian syndromes. Radiographics (2014) 1.41
Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging (2007) 1.09
Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol (2007) 1.07
18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol (2007) 0.92
Reduced striatal D2 receptor binding in myoclonus-dystonia. Eur J Nucl Med Mol Imaging (2008) 0.89
Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT. Eur J Nucl Med Mol Imaging (2012) 0.88
The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging (2005) 0.86
A direct ROI quantification method for inherent PVE correction: accuracy assessment in striatal SPECT measurements. Eur J Nucl Med Mol Imaging (2007) 0.84
CT-based attenuation correction in I-123-ioflupane SPECT. PLoS One (2014) 0.83
Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography. Neurol Sci (2014) 0.83
Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease. Nucl Med Mol Imaging (2011) 0.82
Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. Eur J Nucl Med Mol Imaging (2006) 0.82
Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. Eur J Nucl Med Mol Imaging (2016) 0.82
No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Res (2013) 0.81
Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm (Vienna) (2006) 0.81
Distinguishing Parkinson's disease from atypical parkinsonian syndromes using PET data and a computer system based on support vector machines and Bayesian networks. Front Comput Neurosci (2015) 0.80
Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients. Eur J Nucl Med Mol Imaging (2008) 0.79
Dopamine transporter imaging using 99mTc-TRODAT-1 SPECT in Parkinson's disease. Med Sci Monit (2014) 0.78
PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant Imaging Med Surg (2015) 0.78
Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [(18)F]FP-CIT PET/CT. Nucl Med Mol Imaging (2013) 0.78
Neuroimaging findings in children with paediatric neurotransmitter diseases. J Inherit Metab Dis (2009) 0.76
Evaluation of Iterative Reconstruction Method and Attenuation Correction in Brain Dopamine Transporter SPECT Using an Anthropomorphic Striatal Phantom. Asia Ocean J Nucl Med Biol (2016) 0.75
The relationship between the dopaminergic system and depressive symptoms in cervical dystonia. Eur J Nucl Med Mol Imaging (2017) 0.75
Robust, fully automatic delineation of the head contour by stereotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy. Eur Radiol (2015) 0.75
Computed-tomography-guided anatomic standardization for quantitative assessment of dopamine transporter SPECT. Eur J Nucl Med Mol Imaging (2016) 0.75
Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet (1986) 4.54
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry (1992) 4.16
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Detection by polymerase chain reaction of Treponema pallidum DNA in cerebrospinal fluid from neurosyphilis patients before and after antibiotic treatment. J Clin Microbiol (1991) 2.43
Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature (1981) 2.06
Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide. Eur J Nucl Med (1994) 2.05
Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology (1995) 1.86
White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. Brain (1992) 1.77
Leucoencephalopathy after inhaling "heroin" pyrolysate. Lancet (1982) 1.74
Radiography and scintigraphy of suspected scaphoid fracture. A long-term study in 160 patients. J Bone Joint Surg Br (1993) 1.62
The value of lung scintigraphy in the diagnosis of pulmonary embolism. Eur J Nucl Med (1993) 1.61
Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci (1984) 1.61
[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 1.56
Antigen biological activity ratio for factor VIII in late pregnancy. Lancet (1973) 1.54
[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 1.51
[Compliance with consensus 'Diagnosis pulmonary embolism' in clinical practice]. Ned Tijdschr Geneeskd (1995) 1.49
X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am J Hum Genet (1993) 1.48
Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. Brain (2007) 1.48
A case of progressive aphasia without dementia: "temporal" Pick's disease? J Neurol Neurosurg Psychiatry (1990) 1.42
Evaluation of the long-term functional outcome assessed by myocardial perfusion scintigraphy following excimer laser angioplasty compared to balloon angioplasty in longer coronary lesions. Int J Card Imaging (2000) 1.39
[Diagnostic management in suspicion of pulmonary embolism: results of a survey among Dutch internists and pulmonologists]. Ned Tijdschr Geneeskd (1992) 1.38
Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med (2000) 1.38
Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol (2001) 1.32
Penicillin concentrations in serum and CSF during high-dose intravenous treatment for neurosyphilis. Neurology (1987) 1.30
Intrathecal synthesis of antibodies to HTLV-III in patients without AIDS or AIDS related complex. Br Med J (Clin Res Ed) (1986) 1.30
Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther (1988) 1.29
The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med (2001) 1.28
Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord (2001) 1.23
Chronic manganese intoxication. Arch Neurol (1989) 1.22
A neuromuscular transmission disorder: combined myasthenia gravis and Lambert Eaton syndrome in one patient. J Neurol Neurosurg Psychiatry (1988) 1.22
MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. AJNR Am J Neuroradiol (2000) 1.21
Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest (1989) 1.20
The value of radiographs and bone scintigraphy in suspected scaphoid fracture. A statistical analysis. J Hand Surg Br (1993) 1.19
Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. J Neurol Sci (1994) 1.17
9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current. Eur J Pharmacol (1987) 1.13
Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Ann Neurol (1992) 1.11
Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med (1997) 1.10
Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21. Hum Mol Genet (1996) 1.07
Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A (1992) 1.07
Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med (1998) 1.06
Increased dopamine release from rat striatal slices by inhibitors of GABA-aminotransferase. Eur J Pharmacol (1977) 1.05
Amiodarone pneumonitis: three further cases with a review of published reports. Thorax (1984) 1.04
Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med (1997) 1.04
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov Disord (1994) 1.01
Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med (1999) 1.00
Dopamine D2 receptor stimulation differentially affects voltage-activated calcium channels in rat pituitary melanotropic cells. J Physiol (1992) 1.00
Effect of penicillin on transmitter release from rat cortical tissue. Brain Res (1980) 1.00
Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol (1998) 1.00
Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse (2001) 1.00
One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J Nucl Med (1999) 1.00
[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm (Vienna) (2001) 0.99
Identification of axial rigidity during locomotion in Parkinson disease. Arch Phys Med Rehabil (1999) 0.99
Depression in Parkinson's disease. The impact of symptom overlap on prevalence. Psychosomatics (1998) 0.99
Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med (1997) 0.98
[123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse (1997) 0.98
Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: atypical molecular phenotype. Ann Neurol (2001) 0.97
Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol (1993) 0.96
Uninhibited thyroidal uptake of radioiodine despite iodine excess in amiodarone-induced hypothyroidism. J Clin Endocrinol Metab (1986) 0.95
Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology (Berl) (1999) 0.95